bluebird bio, Inc. (BLUE) Reaches $184.15 After 7.00% Down Move; Casella Waste Systems – Class A (CWST) Shorts Decreased By 13.13%

May 18, 2018 - By Winifred Garcia

Casella Waste Systems, Inc. (NASDAQ:CWST) Logo

The stock of bluebird bio, Inc. (NASDAQ:BLUE) is a huge mover today! The stock decreased 2.72% or $5.15 during the last trading session, reaching $184.15. About 453,157 shares traded. bluebird bio, Inc. (NASDAQ:BLUE) has risen 86.28% since May 18, 2017 and is uptrending. It has outperformed by 74.73% the S&P500.The move comes after 9 months negative chart setup for the $9.23B company. It was reported on May, 18 by Barchart.com. We have $171.26 PT which if reached, will make NASDAQ:BLUE worth $646.03 million less.




Casella Waste Systems Inc – Class A (NASDAQ:CWST) had a decrease of 13.13% in short interest. CWST’s SI was 387,800 shares in May as released by FINRA. Its down 13.13% from 446,400 shares previously. With 370,700 avg volume, 1 days are for Casella Waste Systems Inc – Class A (NASDAQ:CWST)’s short sellers to cover CWST’s short positions. The SI to Casella Waste Systems Inc – Class A’s float is 1.08%. The stock decreased 1.85% or $0.455 during the last trading session, reaching $24.105. About 165,419 shares traded. Casella Waste Systems, Inc. (NASDAQ:CWST) has risen 69.52% since May 18, 2017 and is uptrending. It has outperformed by 57.97% the S&P500.

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. The company has market cap of $9.23 billion. The Company’s product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent beta-thalassemia, and severe sickle cell disease. It currently has negative earnings. The companyÂ’s lead product candidate is bb2121, a chimeric antigen receptor T cell product candidate that is in Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc. to develop and commercialize second generation T cell receptor product candidates against an antigen related to certain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications.

Among 26 analysts covering bluebird bio (NASDAQ:BLUE), 14 have Buy rating, 2 Sell and 10 Hold. Therefore 54% are positive. bluebird bio had 96 analyst reports since August 11, 2015 according to SRatingsIntel. On Monday, December 7 the stock rating was maintained by Jefferies with “Buy”. Roth Capital maintained the stock with “Buy” rating in Friday, August 28 report. The firm has “Neutral” rating given on Thursday, February 22 by Bank of America. The company was maintained on Friday, June 23 by Cowen & Co. Morgan Stanley downgraded the shares of BLUE in report on Monday, October 2 to “Underweight” rating. BMO Capital Markets maintained it with “Buy” rating and $134.0 target in Thursday, August 31 report. The stock of bluebird bio, Inc. (NASDAQ:BLUE) has “Buy” rating given on Wednesday, May 31 by BTIG Research. The firm has “Outperform” rating given on Tuesday, October 20 by Oppenheimer. TH Capital initiated the stock with “Buy” rating in Thursday, December 3 report. The company was initiated on Thursday, December 17 by Stifel Nicolaus.

More notable recent bluebird bio, Inc. (NASDAQ:BLUE) news were published by: Seekingalpha.com which released: “bluebird bio: Gene Therapy Best In Class” on May 16, 2018, also Streetinsider.com with their article: “bluebird bio (BLUE) to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti …” published on May 16, 2018, Streetinsider.com published: “bluebird bio (BLUE) to Present New Data from LentiGlobin Transfusion-Dependent β-Thalassemia and Severe Sickle …” on May 17, 2018. More interesting news about bluebird bio, Inc. (NASDAQ:BLUE) were released by: Fool.com and their article: “Better Buy: Ziopharm Oncology, Inc. vs. bluebird bio Inc.” published on May 12, 2018 as well as Nasdaq.com‘s news article titled: “Is bluebird bio One Step Closer to Its First Commercial Drug?” with publication date: April 20, 2018.

Investors sentiment decreased to 1.51 in Q4 2017. Its down 0.28, from 1.79 in 2017Q3. It fall, as 21 investors sold bluebird bio, Inc. shares while 79 reduced holdings. 71 funds opened positions while 80 raised stakes. 50.71 million shares or 3.40% more from 49.05 million shares in 2017Q3 were reported. Aperio Group Inc Limited Liability Company has 6,496 shares. Covington Capital owns 2,000 shares. 32 are owned by Cwm Ltd. First Manhattan Co holds 400 shares or 0% of its portfolio. Benjamin F Edwards & Com has invested 0% in bluebird bio, Inc. (NASDAQ:BLUE). Weiss Multi accumulated 2,000 shares or 0.01% of the stock. Blackrock Inc holds 3.83M shares or 0.03% of its portfolio. Millennium Mgmt Limited Liability holds 0% or 14,670 shares in its portfolio. Partner Fund Mgmt L P reported 139,791 shares stake. 59,085 were reported by Royal Savings Bank Of Canada. Schwab Charles Mngmt stated it has 296,073 shares. Jane Street Group Lc has 19,168 shares for 0.01% of their portfolio. Winfield Assoc has invested 0.29% in bluebird bio, Inc. (NASDAQ:BLUE). Lincoln Corp has 1,800 shares for 0.01% of their portfolio. Kentucky-based Teachers Retirement Sys Of The State Of Kentucky has invested 0.03% in bluebird bio, Inc. (NASDAQ:BLUE).

Analysts await bluebird bio, Inc. (NASDAQ:BLUE) to report earnings on August, 1. They expect $-2.27 EPS, down 31.21% or $0.54 from last year’s $-1.73 per share. After $-2.31 actual EPS reported by bluebird bio, Inc. for the previous quarter, Wall Street now forecasts -1.73% EPS growth.

Since December 12, 2017, it had 0 insider buys, and 19 insider sales for $6.18 million activity. 19,571 shares valued at $518,467 were sold by CASELLA JOHN W on Tuesday, February 27. $82,458 worth of stock was sold by SCHMITT DAVID L on Tuesday, February 27. On Friday, March 2 Coletta Edmond sold $101,823 worth of Casella Waste Systems, Inc. (NASDAQ:CWST) or 4,184 shares. CASELLA DOUGLAS R had sold 6,978 shares worth $184,590 on Tuesday, February 27. Johnson Edwin D sold $2.08 million worth of stock or 99,091 shares. Shares for $76,433 were sold by Heald Christopher. 15,000 Casella Waste Systems, Inc. (NASDAQ:CWST) shares with value of $315,000 were sold by CALLAHAN JAMES F JR.

More important recent Casella Waste Systems, Inc. (NASDAQ:CWST) news were published by: Seekingalpha.com which released: “Keeping Up With Casella: Q1-18” on May 08, 2018, also Nasdaq.com published article titled: “Casella Waste Systems, Inc. Announces Closing of $550 Million Credit Facility”, Seekingalpha.com published: “Casella Waste Systems’ (CWST) CEO John Casella on Q1 2018 Results – Earnings Call Transcript” on May 05, 2018. More interesting news about Casella Waste Systems, Inc. (NASDAQ:CWST) was released by: Seekingalpha.com and their article: “Comparing Labor In The Waste Industry (1/2): Executive Compensation” with publication date: April 22, 2018.

Casella Waste Systems, Inc., together with its subsidiaries, operates as a vertically-integrated solid waste services firm in the northeastern United States. The company has market cap of $1.03 billion. The firm operates through Eastern Region, Western Region, Recycling, and Other divisions. It currently has negative earnings. It offers resource management services primarily in the areas of solid waste collection and disposal, transfer, recycling, and organics services to residential, commercial, municipal, and industrial customers.

Casella Waste Systems, Inc. (NASDAQ:CWST) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: